These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37099382)

  • 1. Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides.
    Genna V; Iglesias-Fernández J; Reyes-Fraile L; Villegas N; Guckian K; Seth P; Wan B; Cabrero C; Terrazas M; Brun-Heath I; González C; Sciabola S; Villalobos A; Orozco M
    Nucleic Acids Res; 2023 Jun; 51(10):4713-4725. PubMed ID: 37099382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
    Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.
    Wan WB; Migawa MT; Vasquez G; Murray HM; Nichols JG; Gaus H; Berdeja A; Lee S; Hart CE; Lima WF; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Dec; 42(22):13456-68. PubMed ID: 25398895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides.
    Wang S; Allen N; Vickers TA; Revenko AS; Sun H; Liang XH; Crooke ST
    Nucleic Acids Res; 2018 Apr; 46(7):3579-3594. PubMed ID: 29514240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational Design of Chimeric Antisense Oligonucleotides on a Mixed PO-PS Backbone for Splice-Switching Applications.
    Le BT; Chen S; Veedu RN
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.
    Iwamoto N; Butler DCD; Svrzikapa N; Mohapatra S; Zlatev I; Sah DWY; Meena ; Standley SM; Lu G; Apponi LH; Frank-Kamenetsky M; Zhang JJ; Vargeese C; Verdine GL
    Nat Biotechnol; 2017 Sep; 35(9):845-851. PubMed ID: 28829437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins.
    Migawa MT; Shen W; Wan WB; Vasquez G; Oestergaard ME; Low A; De Hoyos CL; Gupta R; Murray S; Tanowitz M; Bell M; Nichols JG; Gaus H; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2019 Jun; 47(11):5465-5479. PubMed ID: 31034558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures of annexin A2-PS DNA complexes show dominance of hydrophobic interactions in phosphorothioate binding.
    Hyjek-Składanowska M; Anderson BA; Mykhaylyk V; Orr C; Wagner A; Poznański JT; Skowronek K; Seth P; Nowotny M
    Nucleic Acids Res; 2023 Feb; 51(3):1409-1423. PubMed ID: 36124719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
    Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
    Nucleic Acids Res; 2017 May; 45(9):5309-5322. PubMed ID: 28379543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and cellular activity of stereochemically-pure 2'-O-(2-methoxyethyl)-phosphorothioate oligonucleotides.
    Li M; Lightfoot HL; Halloy F; Malinowska AL; Berk C; Behera A; Schümperli D; Hall J
    Chem Commun (Camb); 2017 Jan; 53(3):541-544. PubMed ID: 27966701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model.
    Echevarría L; Aupy P; Relizani K; Bestetti T; Griffith G; Blandel F; Komisarski M; Haeberli A; Svinartchouk F; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Jun; 29(3):148-160. PubMed ID: 31009315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly.
    Wang Y; Shen W; Liang XH; Crooke ST
    Nucleic Acid Ther; 2019 Dec; 29(6):343-358. PubMed ID: 31429620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-1,3-Glucan/antisense oligonucleotide complex stabilized with phosphorothioation and its gene suppression.
    Mochizuki S; Sakurai K
    Bioorg Chem; 2010 Dec; 38(6):260-4. PubMed ID: 20673953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Versatile and Convenient Synthesis of
    Stulz R; Meuller J; Baždarević D; Wennberg Huldt C; Strömberg R; Andersson S; Dahlén A
    Chembiochem; 2018 Oct; 19(19):2114-2119. PubMed ID: 30062829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides.
    Lok CN; Viazovkina E; Min KL; Nagy E; Wilds CJ; Damha MJ; Parniak MA
    Biochemistry; 2002 Mar; 41(10):3457-67. PubMed ID: 11876654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorothioates, essential components of therapeutic oligonucleotides.
    Eckstein F
    Nucleic Acid Ther; 2014 Dec; 24(6):374-87. PubMed ID: 25353652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
    Wang S; Allen N; Prakash TP; Liang XH; Crooke ST
    Nucleic Acid Ther; 2019 Oct; 29(5):245-255. PubMed ID: 31158063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins.
    Zhang L; Vickers TA; Sun H; Liang XH; Crooke ST
    Nucleic Acids Res; 2021 Mar; 49(5):2721-2739. PubMed ID: 33577678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.